Monocyte-to-lymphocyte ratio is a prognostic predictor for patients with non-small cell lung cancer treated with stereotactic body radiation therapy.

Autor: Hidekazu Tanaka, Taiki Ono, Miki Kajima, Yuki Manabe, Koya Fujimoto, Yuki Yuasa, Takehiro Shiinoki, Masayuki Matsuo
Zdroj: Reports of Practical Oncology & Radiotherapy; 2024, Vol. 29 Issue 2, p228-235, 8p
Abstrakt: Background: The monocyte-to-lymphocyte ratio (MLR), a systemic inflammation biomarker, has been shown to predict patient outcomes in several types of cancer. This study aimed to determine the association between MLR and local control (LC) and cause-specific survival (CSS) rates in patients with non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT). Materials and methods: The median age of the 194 included participants (144 men, 50 women) was 80 (range, 50-96) years. The median follow-up period was 19 (range, 1--108) months. The LC and CSS rates were calculated using the Kaplan--Meier method. Univariate and multivariate Cox proportional hazard regression models were used to estimate the LC and CSS rates. Results: Local recurrence was observed in 25 patients during the follow-up. Univariate Cox proportional hazards regression analysis revealed that MLR, performance status, and tumor diameter were significant factors for LC. Multivariate analysis showed MLR and tumor diameter as significant factors (p = 0.041 and 0.031, respectively). The 1- and 2-year LC rates for the lower and higher MLR groups were 97.5% and 97.5%, and 89.7% and 81.2%, respectively. During the follow-up period, 14 patients died due to NSCLC. Although MLR tended to predict CSS in univariate analysis (p = 0.086), none of the parameters was significant in predicting CSS. However, MLR as a continuous variable was a significant factor for CSS in the univariate analysis (p = 0.004). Conclusions: Our data suggest that MLR is correlated with LC and CSS rates in NSCLC patients treated with SBRT. [ABSTRACT FROM AUTHOR]
Databáze: Supplemental Index